Eleven Biotherapeutics major shareholder Sells $23,500 in Stock (EBIO)
Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 2,000 shares of Eleven Biotherapeutics stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $11.75, for a total value of $23,500.00. Following the completion of the sale, the insider now directly owns 2,125,291 shares of the company’s stock, valued at approximately $24,972,169. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Eleven Biotherapeutics (NASDAQ:EBIO) traded up 0.59% on Friday, hitting $11.91. The stock had a trading volume of 40,581 shares. Eleven Biotherapeutics has a 52 week low of $9.502 and a 52 week high of $19.333. The stock has a 50-day moving average of $12.08 and a 200-day moving average of $13.01. The company’s market cap is $183.3 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.04. On average, analysts predict that Eleven Biotherapeutics will post $-1.84 earnings per share for the current fiscal year.
Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.